IQVIA has entered into a strategic collaboration with SCRI Development Innovations, the research division of Sarah Cannon Research Institute, to improve the delivery of oncology clinical trials for biopharmaceutical companies. This partnership aims to address common operational barriers, accelerate patient recruitment, and enhance
The Accelero model integrates electronic health record data directly into trial data systems, helping reduce delays in trial activation and improving accuracy. IQVIA will contribute its technological capabilities, including advanced analytics and data management systems, while SCRI brings its history of conducting over 850 early-phase oncology trials. Richard Staub, President of Research & Development Solutions at IQVIA, commented, “This collaboration embodies our commitment to innovation, efficiency, and delivering superior outcomes for patients by bringing together the best of both organizations and eliminating the complexities often associated with multiple vendors. Together we will accelerate the development of new cancer therapies and improve outcomes for patients worldwide.” The joint effort represents a focused step toward faster development and wider availability of new cancer therapies across global markets.